Picture

Ambrx @AmbrxBio

Ambrx (Nasdaq: $AMAM) is developing a pipeline of Engineered Precision Biologics as treatments for cancer indications with a high unmet medical need. Joined February 2023
  • Tweets
    96
  • Followers
    1K
  • Following
    29
  • Likes
    8
AmbrxBio Profile Picture

Ambrx @AmbrxBio

2 months ago

Ambrx is now officially part of @JNJInnovMed. With our world-class team and novel ADC product candidates, we have exciting opportunities ahead to advance and deliver novel targeted therapies for patients with cancer. Read here: investor.jnj.com/news/news-deta…

AmbrxBio Profile Picture

Ambrx @AmbrxBio

4 months ago

We entered into a definitive agreement to be acquired by @JNJNews. We are excited to join a global organization & accelerate our promising pipeline of next-gen ADCs for patients in need of targeted treatment options. For more info & cautionary statements: bit.ly/3NVXqKl

AmbrxBio Profile Picture

Ambrx @AmbrxBio

4 months ago

Our CEO Dan O'Connor comments on Ambrx's transformational year and the Company's addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). Learn more: bit.ly/3GEum65 $AMAM $NBI

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

Ambrx today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. For more information: bit.ly/3GEum65 $AMAM $NBI

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

Thank you @DFCI_BreastOnc for highlighting our poster at #SABCS23 on ACE-Breast-03, our Ph. 2 study of ARX788 in HER2+ #metatastaticbreastcancer patients previously treated with trastuzumab deruxtecan. We look forward to sharing updates on this important work. #breastcancer $AMAM

DFCI_BreastOnc Profile Picture

Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc

5 months ago

Thank you @DFCI_BreastOnc for highlighting our poster at #SABCS23 on ACE-Breast-03, our Ph. 2 study of ARX788 in HER2+ #metatastaticbreastcancer patients previously treated with trastuzumab deruxtecan. We look forward to sharing updates on this important work. #breastcancer $AMAM

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

ARX517, Ambrx's PSMA–directed #AntibodyDrugConjugate (ADC), demonstrated promising safety and efficacy in the APEX-01 trial in patients with #mCRPC. No serious adverse events or DLTs were observed in the Phase 1/2 clinical trial. Read more bit.ly/3t56Agg $AMAM

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

Updated results from the Phase 1/2 APEX-01 clinical trial of ARX517 demonstrate continued safety and anti-tumor activity in patients with metastatic castration-resistant #prostatecancer (#mCRPC). Read more in @UrologyTimes. bit.ly/484KUj0 $AMAM #AntibodyDrugConjugate

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

Our Chief Clinical Officer, Sandra Aung, Ph.D., comments on Ambrx's ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration resistant #prostatecancer (mCRPC). Read more: bit.ly/410TRaP $AMAM

AmbrxBio Profile Picture

Ambrx @AmbrxBio

5 months ago

Ambrx today announced a clinical update regarding its proprietary anti-PSMA ADC ARX517 in the ongoing APEX-01 Phase 1/2 dose escalation and dose expansion clinical trial in metastatic castration resistant #prostatecancer (mCRPC). For details: bit.ly/410TRaP $AMAM

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Dr. Shen spoke with @OncLive about the unique features associated with the use of Ambrx's PSMA–directed #AntibodyDrugConjugate ARX517 in patients with mCRPC and highlighted data presented at #ESMO23 from the ongoing Phase 1/2 APEX-01 trial of ARX517. bit.ly/473VzKK $AMAM

Ambrx retweeted
BiotechTVHQ Profile Picture

BiotechTV @BiotechTVHQ

6 months ago

Company News: @AmbrxBio's CEO & CSO discuss the antibody-drug conjugate space and recent #ESMO23 data. $AMAM Full video: biotechtv.com/post/ambrx-nov…

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

This Sunday, November 5th, Ambrx will walk to raise awareness for #breastcancer at the 2023 San Diego @SusanGKomen #MoreThanPink walk. Learn about the event and join our team here: bit.ly/3u6bUzX #breastcancerAwareness

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Thank you to all who attended Ambrx's KOL event discussing the ARX517 data presented at the 2023 European Society for Medical Oncology Congress meeting. A webcast replay of the event is available here: bit.ly/475J7dj $AMAM #ESMO23 @myESMO #ProstateCancer

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Ambrx's CEO & CSO spoke with @BiotechTVHQ's @bradloncar about our two #AntibodyDrugConjugate programs, ARX788 Anti-HER2 ADC and ARX517 Anti-PSMA ADC, both of which are potential treatments for cancer indications with high unmet medical need. bit.ly/3MuDRYC $AMAM

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

In newly published data from Ambrx's ongoing Ph. 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23, ARX517 was shown to display preliminary efficacy & a strong safety profile in patients with mCRPC. Read more from @OncLive: bit.ly/46NXjYy $AMAM #ProstateCancer

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

.@FierceBiotech highlighted the recent data presented at #ESMO23 from the ongoing Phase 1/2 APEX-01 trial of the #AntibodyDrugConjugate ARX517 in mCRPC showing anti-cancer activity and few adverse events—none serious. Read more: bit.ly/495pyDP $AMAM #ProstateCancer

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Dr. Sartor, a medical oncologist and translational researcher with 33 yrs of professional experience and a special focus on #prostatecancer, comments on the newly published data from the ongoing Ph. 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23 bit.ly/3tM8e6v

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Updated safety, efficacy and PK data from Ambrx’s on-going Phase 1/2 trial, APEX-01, evaluating ARX517 for mCRPC, were made available in clinical posters as part of #ESMO23. For data highlights: bit.ly/3tM8e6v $AMAM #ProstateCancer

AmbrxBio Profile Picture

Ambrx @AmbrxBio

6 months ago

Dr. John Shen, a medical oncologist at UCLA and an investigator on APEX-01, comments on the updated data from the ongoing Phase 1/2 APEX-01 trial of ARX517 in mCRPC presented at #ESMO23. For details: bit.ly/3tM8e6v $AMAM #ProstateCancer

Trends for United States

#TexasHockey
5.296 posts
Wyatt Johnston
2.914 posts
Logan Thompson
#bucciovertimechallenge
3.762 posts
Mike Perry
2.859 posts
#VegasBorn
3.076 posts
Colin Jost
22,3 B posts
Lakers in 7
22,4 B posts
Oklahoma
61,8 B posts
#GagCityMinneapolis
17,9 B posts
#Toonami
3.836 posts
No. Twitter
1,14 Mn posts
Chivas
37 B posts
Hintz
Leafs
34,1 B posts
Marner
13,5 B posts
FaZe
39,9 B posts
Darby
4.084 posts
Feds
57,7 B posts
Ardmore
7.302 posts

You might like

Enjoy the Music Sounds and Views
The Trail
@thetrail99
581 Followers
Aspiring to set a new standard for sustainable mining with critical minerals essential for the clean energy future
South32 Hermosa proje..
@South32Hermosa
624 Followers
MSI leverages your consumer rights and works on your behalf to remove questionable negative items from your credit report. 📊 1-866-217-9841
MSI Credit Solutions
@MSICredit
1K Followers
Bleuwave is a Phoenix General Contractor, Construction, and Finance provider. We bring national contractor experience to the Phoenix area in a boutique package.
Bleuwave
@BleuwaveGC
496 Followers
We're a leading global producer of sustainable specialty #polymers and biobased #pinechemicals used to enhance the performance of products used everyday.
Kraton
@kraton
323 Followers
Grads of Life works with leading employers to create skills-first talent strategies that deliver both business benefits and social impact.
Grads of Life
@gradsoflife
3K Followers
Your Go-to podcast for the innovative minds shaping our nation’s future.
MAC & Bleu - Building..
@macandbleu
469 Followers
Virid is a team of #eCommerce experts providing a comprehensive solution for growing retailers. Here to help: https://t.co/UQOh74s24D
Virid
@teamVirid
3K Followers
Adamas One Corp, The Original Lab-Grown Diamond Company, is a high-quality diamond manufacturer based in the United States. (NASDAQ: $JEWL)
Adamas One Corp
@AdamasOneCorp
1K Followers
American Potential’s mission is to inspire you and equip you with the information you need to raise your voice and be heard.
americanpotential
@AMPotentialPod
1K Followers
ZyVersa (Nasdaq: $ZVSA) is committed to developing biopharmaceuticals that address unmet medical needs of patients with inflammatory and renal diseases.
ZyVersa Therapeutics
@ZyVersaThera
2K Followers
Helping customers overcome the challenges of scaling their #datacenter infrastructure to handle data-driven applications. #ComputationalStorage #NVMe #SSDs
ScaleFlux
@ScaleFlux
2K Followers
NTD Digital is a leading digital marketing agency focused on driving sales, market shares, and bottom line growth for our clients.
NTD Digital
@NTDDigital
1K Followers
8xum IP specializes in patent, trademark, and copyright matters, from the seed of an idea to the final product.
8xum IP
@8xumIP
160 Followers
BTV- #Business Television | 30-min TV show profiling emerging publicly traded companies | CEO Clips: 60-sec executive profiles + commercials #TSX #TSXV #CSE
BTV & CEO Clips
@BTVCeoClips
6K Followers